{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:37:36Z","timestamp":1768714656151,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antigen testing using lateral flow devices (LFDs) plays an important role in the management of the novel coronavirus pandemic of 2019 (COVID-19) by rapidly identifying individuals who are asymptomatically carrying high levels of the virus. By January 2021, LFD community testing sites were set up across English local authority areas to support the management and containment of regional COVID-19 cases, initially targeting essential workers unable to work from home during the national lockdown. This study aimed to examine the characteristics and motivations of individuals accessing community LFD testing across two local authority areas (LAAs) in the South West of England.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were collected as part of a service evaluation from December 22<jats:sup>nd<\/jats:sup> 2020 until March 15<jats:sup>th<\/jats:sup> 2021 for two LAAs. Demographic and postcode data were collected from an online test appointment booking platform and the National Health Service testing service online system, with data accessed from Public Health England. An online survey was sent to individuals who made a testing appointment at an LAA1 site using the online booking platform, consisting of 12 questions to collect data on individual\u2019s motivations for and experiences of testing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data were available for individuals who completed 12,516 tests in LAA1 and 12,327 tests in LAA2. Most individuals who engaged with testing were female, working age, white, and worked as early years or education staff, health and social care staff, and supermarket or food production staff. 1249 individuals completed the survey with 60% of respondents reported getting tested for work-related reasons. Individuals first heard about LFD testing through various channels including work, media, and word of mouth, and decided to get tested based on the ease and convenience of testing, workplace communications, and to identify asymptomatic cases to help stop the spread. Most tests were completed by individuals living in less deprived areas based on national deciles of deprivation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>While national and local COVID-19 testing strategies have evolved, community and personal LFD testing remains a crucial pillar of the testing strategy. Future studies should collect quantitative and qualitative data from residents to most effectively shape testing offers based on the needs and preferences of their population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-022-12986-4","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T23:02:23Z","timestamp":1648249343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Who is accessing community lateral flow device testing and why? Characteristics and motivations of individuals participating in COVID-19 community testing in two English local authority areas"],"prefix":"10.1186","volume":"22","author":[{"given":"Michael N.","family":"Dalili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Wadley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyla H.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"issue":"2","key":"12986_CR1","first-page":"97","volume":"10","author":"M Shen","year":"2020","unstructured":"Shen M, Zhou Y, Ye J, Abdullah Al-maskri AA, Kang Y, Zeng S, et al. Recent advances and perspectives of nucleic acid detection for coronavirus. J Pharmaceut Anals. 2020;10(2):97\u2013101.","journal-title":"J Pharmaceut Anals"},{"key":"12986_CR2","doi-asserted-by":"crossref","unstructured":"Teymouri M, Mollazadeh S, Mortazavi H, Naderi Ghale-noie Z, Keyvani V, Aghababaei F, et al. Recent advances and challenges of RT-PCR tests for the diagnosis of COVID-19. Pathology - Research and Practice. 2021;221:153443.","DOI":"10.1016\/j.prp.2021.153443"},{"key":"12986_CR3","doi-asserted-by":"crossref","unstructured":"Crozier A, Rajan S, Buchan I, McKee M. Put to the test: use of rapid testing technologies for covid-19. BMJ. 2021;372:n208.","DOI":"10.1136\/bmj.n208"},{"key":"12986_CR4","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Fi\u00f1ana M, Hughes DM, Cheyne CP, Burnside G, Stockbridge M, Fowler TA, et al. Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study. BMJ. 2021;374:n1637.","DOI":"10.1136\/bmj.n1637"},{"key":"12986_CR5","doi-asserted-by":"crossref","unstructured":"Lee LYW, Rozmanowski S, Pang M, Charlett A, Anderson C, Hughes GJ, et al. SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission. Clin Infect Dis. 2021.","DOI":"10.1101\/2021.03.31.21254687"},{"key":"12986_CR6","doi-asserted-by":"crossref","unstructured":"Lee LYW, Rozmanowski S, Pang M, Charlett A, Anderson C, Hughes GJ, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity by Viral Load, S Gene Variants and Demographic Factors, and the Utility of Lateral Flow Devices to Prevent Transmission. Clin Infect Dis. 2021.","DOI":"10.1093\/cid\/ciab421"},{"key":"12986_CR7","doi-asserted-by":"crossref","unstructured":"Kmietowicz Z. Covid-19: Controversial rapid test policy divides doctors and scientists. BMJ. 2021;372:n81.","DOI":"10.1136\/bmj.n81"},{"key":"12986_CR8","doi-asserted-by":"crossref","unstructured":"Mahase E. Covid-19: Innova lateral flow test is not fit for \u201ctest and release\u201d strategy, say experts. BMJ. 2020;371:m4469.","DOI":"10.1136\/bmj.m4469"},{"key":"12986_CR9","doi-asserted-by":"crossref","unstructured":"Mahase E. Covid-19: UK regulator approves lateral flow test for home use despite accuracy concerns. BMJ. 2020;371:m4950.","DOI":"10.1136\/bmj.m4950"},{"key":"12986_CR10","doi-asserted-by":"crossref","unstructured":"Pugh J, Wilkinson D, Savulescu J. Sense and sensitivity: can an inaccurate test be better than no test at all? J Med Ethics. 2021:medethics-2021\u2013107234.","DOI":"10.1136\/medethics-2021-107234"},{"key":"12986_CR11","doi-asserted-by":"crossref","unstructured":"Wise J. Covid-19: Lateral flow tests miss over half of cases, Liverpool pilot data show. BMJ. 2020;371:m4848.","DOI":"10.1136\/bmj.m4848"},{"key":"12986_CR12","doi-asserted-by":"crossref","unstructured":"Deeks JJ, Raffle AE. Lateral flow tests cannot rule out SARS- CoV-2 infection. BMJ. 2020;371:m4787.","DOI":"10.1136\/bmj.m4787"},{"key":"12986_CR13","doi-asserted-by":"crossref","unstructured":"Mahase E. Covid-19: People are not being warned about pitfalls of mass testing. BMJ. 2021;372:n238.","DOI":"10.1136\/bmj.n238"},{"issue":"4","key":"12986_CR14","doi-asserted-by":"publisher","first-page":"e3001216","DOI":"10.1371\/journal.pbio.3001216","volume":"19","author":"J Ferguson","year":"2021","unstructured":"Ferguson J, Dunn S, Best A, Mirza J, , Percival B, , Mayhew M, et al. Validation testing to determine the sensitivity of lateral flow testing for asymptomatic SARS-CoV-2 detection in low prevalence settings: Testing frequency and public health messaging is key. PLoS Biol. 2021;19(4):e3001216.","journal-title":"PLoS Biol"},{"key":"12986_CR15","unstructured":"UK Government. COVID-19 Winter Plan 2020 [updated 2 December 2020. Available from: https:\/\/www.gov.uk\/government\/publications\/covid-19-winter-plan]."},{"key":"12986_CR16","unstructured":"UK Government. Asymptomatic testing for SARS-CoV-2 using antigen-detecting lateral flow devices. Evidence from performance data October 2020 \u2013 May 2021. 2021 [updated 7 July 2021. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/999866\/asymptomatic-testing-for-SARS-CoV-2-using-antigen-detecting-lateral-flow-devices-evidence-from-performance-data-Oct-2020-to-May-2021.pdf]."},{"key":"12986_CR17","unstructured":"Office for National Statistics. Employment by Occupation (SOC2010) by sex 2020 [Available from: https:\/\/www.nomisweb.co.uk\/datasets\/aps168\/reports\/employment-by-occupation?compare=K02000001]."},{"key":"12986_CR18","doi-asserted-by":"crossref","unstructured":"Green MA, Garc\u00eda-Fi\u00f1ana M, Barr B, Burnside G, Cheyne CP, Hughes D, et al. Evaluating social and spatial inequalities of large scale rapid lateral flow SARS-CoV-2 antigen testing in COVID-19 management: An observational study of Liverpool, UK (November 2020 to January 2021). Lancet Reg Health Eur. 2021;6:100107-.","DOI":"10.1016\/j.lanepe.2021.100107"},{"key":"12986_CR19","doi-asserted-by":"crossref","unstructured":"Bevan I, Stage Baxter M, Stagg HR, Street A. Knowledge, Attitudes, and Behavior Related to COVID-19 Testing: A Rapid Scoping Review. Diagnostics (Basel). 2021;11(9).","DOI":"10.3390\/diagnostics11091685"},{"issue":"1","key":"12986_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12889-022-12657-4","volume":"22","author":"D Watson","year":"2022","unstructured":"Watson D, Baralle NL, Alagil J, Anil K, Ciccognani S, Dewar-Haggart R, et al. How do we engage people in testing for COVID-19? A rapid qualitative evaluation of a testing programme in schools, GP surgeries and a university. BMC Public Health. 2022;22(1):305.","journal-title":"BMC Public Health"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-12986-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-022-12986-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-12986-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T23:02:35Z","timestamp":1648249355000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-022-12986-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["12986"],"URL":"https:\/\/doi.org\/10.1186\/s12889-022-12986-4","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this work as data was collected as part of a service evaluation of the LFD testing programme in each LAA. We made sure we used personal information according to the UK Data Protection laws by establishing the following lawful conditions of Article 6(1)(e)\u2014public task to process the personal data and Article 9(2)(g) \u2013 substantial public interest, and para 6 of Schedule 1 of the Data Protection Act \u2013 governmental purpose to process and share this data. We also had a statutory requirement to process any such confidential patient information for purposes set out in Regulation 3(1) of the Health Service Control of Patient Information Regulations 2002 (COPI) under the notice dated 20th March 2020 issued to them by the Secretary of State for Health and Social Care under Regulation 3(4) of COPI (the COPI Notice) until 20th September 2020.As such, this allowed us to contact individuals who had booked a testing appointment using the online booking platform for LAA1 test sites. Survey completion was voluntary, and individuals could opt out of the survey at any time by navigating away from the page or closing the web browser. Individuals were informed about the purpose of the survey, why they were being contacted, and that their data would be anonymised once returned, with any personal data removed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"588"}}